Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) were down 7.4% during trading on Friday . The company traded as low as $1.10 and last traded at $1.13. Approximately 1,580,112 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 1,219,598 shares. The stock had previously closed at $1.22.
Separately, Roth Capital initiated coverage on Matinas BioPharma in a research report on Monday, February 11th. They set a “buy” rating and a $4.75 target price on the stock.
Institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC raised its position in Matinas BioPharma by 100.4% during the fourth quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after buying an additional 24,978 shares during the period. Northern Trust Corp raised its position in Matinas BioPharma by 18.9% during the fourth quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock valued at $109,000 after buying an additional 29,072 shares during the period. D. E. Shaw & Co. Inc. acquired a new position in Matinas BioPharma during the fourth quarter valued at $26,000. Virtu Financial LLC acquired a new position in Matinas BioPharma during the fourth quarter valued at $39,000. Finally, Renaissance Technologies LLC raised its position in Matinas BioPharma by 325.6% during the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $124,000 after buying an additional 103,200 shares during the period.
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Recommended Story: Institutional Investors
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.